Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

Clin Infect Dis. 2004 Nov 15;39(10):1520-3. doi: 10.1086/425359. Epub 2004 Oct 18.

Abstract

Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed. Initial response was achieved in 25 patients (64%), including 16 patients (43%) with initial parasitological cure. Repeated responses after relapse and tolerability of long courses of treatment indicate the potential for development of optimized dosage schemes.

MeSH terms

  • Administration, Oral
  • Adult
  • Antiprotozoal Agents / administration & dosage*
  • Female
  • HIV Infections / complications*
  • Humans
  • Immunocompromised Host
  • Leishmaniasis / drug therapy*
  • Leishmaniasis / etiology*
  • Leishmaniasis / immunology
  • Male
  • Middle Aged
  • Phosphorylcholine / administration & dosage
  • Phosphorylcholine / analogs & derivatives*

Substances

  • Antiprotozoal Agents
  • Phosphorylcholine
  • miltefosine